Literature DB >> 10065628

Vaccinia virus immune evasion.

G L Smith1.   

Abstract

Vaccinia virus expresses many virulence factors that are non-essential for virus replication in cell culture but are important in vivo. In this paper three mechanisms are described that are used by vaccinia virus to evade the host immune response to infection. One of these is the release of a soluble protein that binds CC chemokines and that is unrelated to cellular chemokine receptors. The other two mechanisms are displayed by virus particles that are released from infected cells. This form of vaccinia virus is called extracellular enveloped virus (EEV) and is resistant to neutralisation by antibody and to destruction by complement. Resistance to complement is mediated by the acquisition of host complement control proteins, particularly CD55, during virus release from infected cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065628     DOI: 10.1016/s0165-2478(98)00125-4

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  18 in total

1.  N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.

Authors:  Meike S Gratz; Yasemin Suezer; Melanie Kremer; Asisa Volz; Monir Majzoub; Kay-Martin Hanschmann; Ulrich Kalinke; Astrid Schwantes; Gerd Sutter
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

Authors:  J Hughes; P Wang; G Alusi; H Shi; Y Chu; J Wang; V Bhakta; I McNeish; A McCart; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2015-04-16       Impact factor: 5.250

3.  Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy.

Authors:  Crystal C Walline; Sarah N Deffit; Nan Wang; Lynette M Guindon; Victoria L Crotzer; Jianyun Liu; Kristin Hollister; Laurence C Eisenlohr; Randy R Brutkiewicz; Mark H Kaplan; Janice S Blum
Journal:  Immunology       Date:  2014-04       Impact factor: 7.397

4.  Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3.

Authors:  J Musil; L Kutinova; K Zurkova; P Hainz; K Babiarova; J Krystofova; S Nemeckova
Journal:  Cancer Gene Ther       Date:  2014-02-21       Impact factor: 5.987

5.  Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model.

Authors:  T A Brandt; B L Jacobs
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Intracellular localization of vaccinia virus extracellular enveloped virus envelope proteins individually expressed using a Semliki Forest virus replicon.

Authors:  M M Lorenzo; I Galindo; G Griffiths; R Blasco
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses.

Authors:  Mohamed R Mohamed; Masmudur M Rahman; Jerry S Lanchbury; Donna Shattuck; Chris Neff; Max Dufford; Nick van Buuren; Katharine Fagan; Michele Barry; Scott Smith; Inger Damon; Grant McFadden
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

8.  Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-kappa B) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus.

Authors:  Surendran Mahalingam; Brett A Lidbury
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-03       Impact factor: 11.205

9.  The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.

Authors:  Ralph A Tripp; Azzeddine Dakhama; Les P Jones; Albert Barskey; Erwin W Gelfand; Larry J Anderson
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Functional characterization of the vaccinia virus I5 protein.

Authors:  Bethany Unger; R Jeremy Nichols; Eleni S Stanitsa; Paula Traktman
Journal:  Virol J       Date:  2008-12-15       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.